Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

MicroRNA Isoforms for Molecular Interception of Cervical cancer using Self-samples

Objective

With 13,000 deaths each year in the EU, cervical cancer (CC) is one of the deadliest cancers worldwide. This is unnecessary, since CC is well detectable and treatable at early stages. For this reason, most EU countries have screening programs in place. These screening programs have had (varying) success in reducing CC incidence, however, this reduction has reached a plateau and new strategies are needed to improve screening success.
An important reason for the stagnating decline in CC incidence is the relative high rate of non-compliance to screening because the gynaecological procedure to collect a sample is seen as highly uncomfortable and very invasive. Offering self-sampling options increases the participation rate in non-responder women by 30%. However, self-sampling is not compatible with the current cytology-based screening method (e.g. Pap test). There is thus a great need for the development of new, molecular screening assays for CC that can be used on self-samples.
In the ERC-AdG MASS-CARE, we investigate the value of two classes of molecular markers, DNA methylation and miRNA for the detection of cervical disease in self-samples. In our analyses, we frequently observed variations at the 3’ end of the miRNA markers. Such variations (isomiRs) have great impact on their detectability by standard assays and thus specific assay development for these isomiRs constitutes a great improvement compared to using the canonical miRNA sequence.
In MIMICS, we aim to select the isomiRs with the strongest association with CC which therefore have added value as disease biomarker compared to the canonical miRNAs. The identified isomiRs, which improve CC detection compared to the canonical miRNAs will be added to the panel of DNA methylation and canonical miRNAs as identified in the ERC-AdG. This assay will constitute the first full molecular, non-morphology-based, objective screening assay for cervical cancer fully compatible with self-sampling.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2015-PoC

See all projects funded under this call

Host institution

STICHTING AMSTERDAM UMC
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 150 000,00

Beneficiaries (1)

My booklet 0 0